{"id":"https://openalex.org/W7225149145","doi":"https://doi.org/10.1136/jitc-2026-sitc2026.0895","title":"895 Engineering GPRC5D multispecific antibodies: parallel engineering to optimize affinity, developability, and IP","display_name":"895 Engineering GPRC5D multispecific antibodies: parallel engineering to optimize affinity, developability, and IP","publication_year":2026,"publication_date":"2026-11-01","ids":{"openalex":"https://openalex.org/W7225149145","doi":"https://doi.org/10.1136/jitc-2026-sitc2026.0895"},"language":"en","primary_location":{"id":"doi:10.1136/jitc-2026-sitc2026.0895","doi":"https://doi.org/10.1136/jitc-2026-sitc2026.0895","is_oa":true,"landing_page_url":"https://doi.org/10.1136/jitc-2026-sitc2026.0895","pdf_url":"https://jitc.bmj.com/content/14/Suppl_2/A1014.full.pdf","source":{"id":"https://openalex.org/S2754803477","display_name":"Journal for ImmunoTherapy of Cancer","issn_l":"2051-1426","issn":["2051-1426"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-b","doyens","jufo-2","ki-jl-2","medline","norway-2","oarl","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310319945","host_organization_name":"BMJ","host_organization_lineage":["https://openalex.org/P4310319945"],"host_organization_lineage_names":["BMJ"],"type":"journal"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Regular Abstracts","raw_type":"proceedings-article"},"volume":null,"type":"conference-abstract","is_traditional":false,"indexed_in":["crossref","doaj"],"open_access":{"is_oa":true,"oa_status":"gold","oa_url":"https://jitc.bmj.com/content/14/Suppl_2/A1014.full.pdf","any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5066289791","display_name":"Trevor Barnes","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210140826","display_name":"Integral Molecular (United States)","ror":"https://ror.org/056pdk382","country_code":"US","type":"company","lineage":["https://openalex.org/I4210140826"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Trevor Barnes","raw_affiliation_strings":["Integral Molecular, Philadelphia, PA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Integral Molecular, Philadelphia, PA, USA","institution_ids":["https://openalex.org/I4210140826"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5113738468","display_name":"Hayley Roth","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210140826","display_name":"Integral Molecular (United States)","ror":"https://ror.org/056pdk382","country_code":"US","type":"company","lineage":["https://openalex.org/I4210140826"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Hayley Roth","raw_affiliation_strings":["Integral Molecular, Philadelphia, PA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Integral Molecular, Philadelphia, PA, USA","institution_ids":["https://openalex.org/I4210140826"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5160540460","display_name":"Daniel Rogers","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210140826","display_name":"Integral Molecular (United States)","ror":"https://ror.org/056pdk382","country_code":"US","type":"company","lineage":["https://openalex.org/I4210140826"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Daniel Rogers","raw_affiliation_strings":["Integral Molecular, Philadelphia, PA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Integral Molecular, Philadelphia, PA, USA","institution_ids":["https://openalex.org/I4210140826"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5021339320","display_name":"Ileine M. Sanchez","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210140826","display_name":"Integral Molecular (United States)","ror":"https://ror.org/056pdk382","country_code":"US","type":"company","lineage":["https://openalex.org/I4210140826"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Ileine Sanchez","raw_affiliation_strings":["Integral Molecular, Philadelphia, PA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Integral Molecular, Philadelphia, PA, USA","institution_ids":["https://openalex.org/I4210140826"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5092124308","display_name":"Valerie Fiers","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210140826","display_name":"Integral Molecular (United States)","ror":"https://ror.org/056pdk382","country_code":"US","type":"company","lineage":["https://openalex.org/I4210140826"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Valerie Fiers","raw_affiliation_strings":["Integral Molecular, Philadelphia, PA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Integral Molecular, Philadelphia, PA, USA","institution_ids":["https://openalex.org/I4210140826"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5057083930","display_name":"Breanna Tyrell","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210140826","display_name":"Integral Molecular (United States)","ror":"https://ror.org/056pdk382","country_code":"US","type":"company","lineage":["https://openalex.org/I4210140826"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Breanna Tyrell","raw_affiliation_strings":["Integral Molecular, Philadelphia, PA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Integral Molecular, Philadelphia, PA, USA","institution_ids":["https://openalex.org/I4210140826"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5160415719","display_name":"Amelia Snyde","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210140826","display_name":"Integral Molecular (United States)","ror":"https://ror.org/056pdk382","country_code":"US","type":"company","lineage":["https://openalex.org/I4210140826"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Amelia Snyde","raw_affiliation_strings":["Integral Molecular, Philadelphia, PA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Integral Molecular, Philadelphia, PA, USA","institution_ids":["https://openalex.org/I4210140826"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5022558900","display_name":"Kyle Doolan","orcid":"https://orcid.org/0000-0001-8449-4826","observed_orcids":["https://orcid.org/0000-0001-8449-4826"]},"institutions":[{"id":"https://openalex.org/I4210140826","display_name":"Integral Molecular (United States)","ror":"https://ror.org/056pdk382","country_code":"US","type":"company","lineage":["https://openalex.org/I4210140826"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Kyle Doolan","raw_affiliation_strings":["Integral Molecular, Philadelphia, PA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Integral Molecular, Philadelphia, PA, USA","institution_ids":["https://openalex.org/I4210140826"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5114524750","display_name":"Alexander Hobby","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210140826","display_name":"Integral Molecular (United States)","ror":"https://ror.org/056pdk382","country_code":"US","type":"company","lineage":["https://openalex.org/I4210140826"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Alexander Hobby","raw_affiliation_strings":["Integral Molecular, Philadelphia, PA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Integral Molecular, Philadelphia, PA, USA","institution_ids":["https://openalex.org/I4210140826"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5065019518","display_name":"Benjamin J. Doranz","orcid":"https://orcid.org/0000-0002-8245-3083","observed_orcids":["https://orcid.org/0000-0002-8245-3083"]},"institutions":[{"id":"https://openalex.org/I4210140826","display_name":"Integral Molecular (United States)","ror":"https://ror.org/056pdk382","country_code":"US","type":"company","lineage":["https://openalex.org/I4210140826"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Benjamin Doranz","raw_affiliation_strings":["Integral Molecular, Philadelphia, PA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Integral Molecular, Philadelphia, PA, USA","institution_ids":["https://openalex.org/I4210140826"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5077283279","display_name":"Ross Chambers","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210140826","display_name":"Integral Molecular (United States)","ror":"https://ror.org/056pdk382","country_code":"US","type":"company","lineage":["https://openalex.org/I4210140826"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Ross Chambers","raw_affiliation_strings":["Integral Molecular, Philadelphia, PA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Integral Molecular, Philadelphia, PA, USA","institution_ids":["https://openalex.org/I4210140826"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5112235589","display_name":"Joseph B. Rucker","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210140826","display_name":"Integral Molecular (United States)","ror":"https://ror.org/056pdk382","country_code":"US","type":"company","lineage":["https://openalex.org/I4210140826"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Joseph Rucker","raw_affiliation_strings":["Integral Molecular, Philadelphia, PA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Integral Molecular, Philadelphia, PA, USA","institution_ids":["https://openalex.org/I4210140826"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":[],"corresponding_institution_ids":["https://openalex.org/I4210140826"],"apc_list":{"value":2490,"currency":"USD","value_usd":2490},"apc_paid":{"value":2490,"currency":"USD","value_usd":2490},"fwci":null,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":null,"issue":null,"first_page":"A1014","last_page":"A1014"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11016","display_name":"Monoclonal and Polyclonal Antibodies Research","score":0.9970999956130981,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T11016","display_name":"Monoclonal and Polyclonal Antibodies Research","score":0.9970999956130981,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10649","display_name":"Multiple Myeloma Research and Treatments","score":0.0020000000949949026,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T12534","display_name":"Protein Degradation and Inhibitors","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/gprc5d","display_name":"GPRC5D","score":0.9810000061988831},{"id":"https://openalex.org/keywords/multispecific-antibodies","display_name":"multispecific antibodies","score":0.9150000214576721},{"id":"https://openalex.org/keywords/t-cell-engaging-antibody","display_name":"T cell-engaging antibody","score":0.7799999713897705},{"id":"https://openalex.org/keywords/multiple-myeloma","display_name":"multiple myeloma","score":0.8820000290870667},{"id":"https://openalex.org/keywords/b-cell-maturation-antigen","display_name":"BCMA","score":0.8640000224113464},{"id":"https://openalex.org/keywords/cd3","display_name":"CD3","score":0.9570000171661377},{"id":"https://openalex.org/keywords/affinity-maturation","display_name":"affinity maturation","score":0.9319999814033508},{"id":"https://openalex.org/keywords/antibody-developability","display_name":"antibody developability","score":0.6320000290870667},{"id":"https://openalex.org/keywords/cross-species-reactivity","display_name":"cross-species reactivity","score":0.8679999709129333},{"id":"https://openalex.org/keywords/cynomolgus-monkeys","display_name":"Macaca fascicularis","score":0.5979999899864197},{"id":"https://openalex.org/keywords/g-protein-coupled-receptors","display_name":"G protein-coupled receptors","score":0.7049999833106995},{"id":"https://openalex.org/keywords/off-target-binding","display_name":"off-target binding","score":0.515999972820282}],"concepts":[{"id":"https://openalex.org/C41008148","wikidata":"https://www.wikidata.org/wiki/Q21198","display_name":"Computer science","level":0,"score":0.6430000066757202},{"id":"https://openalex.org/C115903868","wikidata":"https://www.wikidata.org/wiki/Q80993","display_name":"Software engineering","level":1,"score":0.4578999876976013},{"id":"https://openalex.org/C201995342","wikidata":"https://www.wikidata.org/wiki/Q682496","display_name":"Systems engineering","level":1,"score":0.2824999988079071},{"id":"https://openalex.org/C127413603","wikidata":"https://www.wikidata.org/wiki/Q11023","display_name":"Engineering","level":0,"score":0.25380000472068787},{"id":"https://openalex.org/C106515295","wikidata":"https://www.wikidata.org/wiki/Q26806595","display_name":"Parallel processing","level":2,"score":0.2502000033855438},{"id":"https://openalex.org/C120314980","wikidata":"https://www.wikidata.org/wiki/Q180634","display_name":"Distributed computing","level":1,"score":0.24709999561309814},{"id":"https://openalex.org/C149635348","wikidata":"https://www.wikidata.org/wiki/Q193040","display_name":"Embedded system","level":1,"score":0.24240000545978546},{"id":"https://openalex.org/C70721500","wikidata":"https://www.wikidata.org/wiki/Q177005","display_name":"Computational biology","level":1,"score":0.23019999265670776},{"id":"https://openalex.org/C118524514","wikidata":"https://www.wikidata.org/wiki/Q173212","display_name":"Computer architecture","level":1,"score":0.218299999833107},{"id":"https://openalex.org/C199360897","wikidata":"https://www.wikidata.org/wiki/Q9143","display_name":"Programming language","level":1,"score":0.21170000731945038}],"mesh":[],"locations_count":2,"locations":[{"id":"doi:10.1136/jitc-2026-sitc2026.0895","doi":"https://doi.org/10.1136/jitc-2026-sitc2026.0895","is_oa":true,"landing_page_url":"https://doi.org/10.1136/jitc-2026-sitc2026.0895","pdf_url":"https://jitc.bmj.com/content/14/Suppl_2/A1014.full.pdf","source":{"id":"https://openalex.org/S2754803477","display_name":"Journal for ImmunoTherapy of Cancer","issn_l":"2051-1426","issn":["2051-1426"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-b","doyens","jufo-2","ki-jl-2","medline","norway-2","oarl","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310319945","host_organization_name":"BMJ","host_organization_lineage":["https://openalex.org/P4310319945"],"host_organization_lineage_names":["BMJ"],"type":"journal"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Regular Abstracts","raw_type":"proceedings-article"},{"id":"pmh:oai:doaj.org/article:0747cac176764f7c9aaafc6b3adc653c","doi":null,"is_oa":false,"landing_page_url":"https://doaj.org/article/0747cac176764f7c9aaafc6b3adc653c","pdf_url":null,"source":{"id":"https://openalex.org/S4306401280","display_name":"DOAJ (DOAJ: Directory of Open Access Journals)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"Journal for ImmunoTherapy of Cancer, Vol 14, Iss Suppl 2 (2026)","raw_type":"article"}],"best_oa_location":{"id":"doi:10.1136/jitc-2026-sitc2026.0895","doi":"https://doi.org/10.1136/jitc-2026-sitc2026.0895","is_oa":true,"landing_page_url":"https://doi.org/10.1136/jitc-2026-sitc2026.0895","pdf_url":"https://jitc.bmj.com/content/14/Suppl_2/A1014.full.pdf","source":{"id":"https://openalex.org/S2754803477","display_name":"Journal for ImmunoTherapy of Cancer","issn_l":"2051-1426","issn":["2051-1426"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-b","doyens","jufo-2","ki-jl-2","medline","norway-2","oarl","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310319945","host_organization_name":"BMJ","host_organization_lineage":["https://openalex.org/P4310319945"],"host_organization_lineage_names":["BMJ"],"type":"journal"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Regular Abstracts","raw_type":"proceedings-article"},"sustainable_development_goals":[{"score":0.8199999928474426,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":true,"grobid_xml":false},"content_urls":{"pdf":"https://content.openalex.org/works/W7225149145.pdf"},"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W7225200230","https://openalex.org/W7225193294","https://openalex.org/W2911584837","https://openalex.org/W359928607","https://openalex.org/W4314937414","https://openalex.org/W7144898681","https://openalex.org/W4230216733","https://openalex.org/W7225194482","https://openalex.org/W2969247675","https://openalex.org/W2003865330"],"abstract_inverted_index":{"Background":[0],"GPRC5D":[1,32,82,116,122,126,297,319,341],"is":[2],"a":[3,79,95,155,235,253,337],"G":[4],"protein-coupled":[5],"receptor":[6],"expressed":[7],"on":[8,230],"multiple":[9,231,249,330],"myeloma":[10,232,250],"cells":[11,43],"but":[12,58],"largely":[13],"absent":[14],"from":[15],"healthy":[16],"tissues,":[17],"making":[18],"it":[19],"an":[20],"attractive":[21],"target":[22],"for":[23,61,97,104,111,135,157,185,191,214,329,357],"T":[24,42,224],"cell-engaging":[25],"multispecific":[26,219,320],"antibodies.":[27],"Antibodies":[28,114],"that":[29,221],"simultaneously":[30],"engage":[31],"and":[33,38,68,84,89,108,119,125,138,144,153,189,193,198,210,241,244,300,326,353],"additional":[34],"molecules":[35,132],"(e.g.":[36],"BCMA":[37,128],"CD3)":[39],"to":[40,46,65,169,263,294,306],"activate":[41],"are":[44,54,335],"anticipated":[45],"provide":[47],"excellent":[48],"efficacy":[49],"as":[50,87,121,324],"monotherapies.Multipass":[51],"membrane":[52,73,273],"proteins":[53],"valuable":[55],"therapeutic":[56],"targets":[57],"often":[59],"inaccessible":[60],"antibody":[62,103,287],"discovery":[63,75],"due":[64],"structural":[66],"complexity":[67],"high":[69],"conservation.":[70],"Using":[71],"our":[72,101,149],"protein-optimized":[74],"platform,":[76],"we":[77,151,334],"generated":[78],"panel":[80],"of":[81,100,276,280,284,340],"antibodies":[83,220,321,342],"engineered":[85],"them":[86],"bi-":[88],"trispecific":[90],"molecules.":[91],"We":[92,217],"also":[93],"developed":[94,152],"platform":[96],"comprehensive":[98,158],"CDR-Scanning":[99,159],"lead":[102,286],"affinity":[105,347],"maturation,":[106],"developability,":[107],"cross-species":[109],"reactivity":[110,194],"preclinical":[112,358],"testing.Methods":[113],"against":[115,195,248],"were":[117,133,182,206],"isolated":[118],"formatted":[120],"\u00d7":[123,127,129],"CD3":[124],"CD3.":[130],"These":[131],"tested":[134],"in":[136,139,252,355],"vitro":[137],"vivo":[140],"potency,":[141],"cytokine":[142,242],"release,":[143],"binding":[145,186,262,293,305,316],"specificity.To":[146],"further":[147,215],"optimize":[148],"lead,":[150],"optimized":[154],"method":[156],"where":[160],"each":[161],"residue":[162,179],"across":[163,271],"6":[164],"CDR":[165,278],"regions":[166,279],"was":[167],"substituted":[168],"all":[170],"19":[171],"other":[172],"amino":[173],"acid":[174],"variants,":[175],"generating":[176],"986":[177],"single":[178],"variants.":[180],"Variants":[181],"individually":[183],"evaluated":[184],"using":[187,208],"ELISA":[188],"assessed":[190],"expression":[192],"both":[196],"human":[197,296],"cynomolgus":[199,307,356],"GPRC5D.":[200,308],"Beneficial":[201],"substitutions":[202],"(>200%":[203],"wild-type":[204],"binding)":[205],"combined":[207],"structure-guided":[209],"AI/ML-informed":[211],"design":[212],"strategies":[213],"validation.Results":[216],"identified":[218,288],"exhibited":[222],"potent":[223,325],"cell-mediated":[225],"cytotoxicity":[226],"with":[227,291,303,315,343],"picomolar":[228],"potency":[229],"cell":[233,239],"lines,":[234],"large":[236],"window":[237],"between":[238],"killing":[240],"release":[243],"robust":[245],"tumor":[246],"control":[247],"xenografts":[251],"humanized":[254],"mouse":[255],"model.":[256],"Antibody":[257],"specificity":[258],"profiling":[259],"confirmed":[260],"high-specificity":[261],"the":[264,272,277,281,285,295],"intended":[265],"targets,":[266],"without":[267],"detectable":[268],"off-target":[269],"interactions":[270],"proteome.Saturating":[274],"mutagenesis":[275],"GPRC5D-binding":[282],"moiety":[283],"14":[289],"variants":[290,302,314],"elevated":[292,304],">200%":[298],"WT,":[299],"10":[301],"Combination":[309],"yielded":[310],"more":[311],"than":[312],"20":[313],">4,000%":[317],"WT.Conclusions":[318],"hold":[322],"promise":[323],"safe":[327],"therapeutics":[328],"myeloma.":[331],"Through":[332],"CDR-Scanning,":[333],"advancing":[336],"new":[338],"generation":[339],"enhanced":[344],"attributes,":[345],"including":[346],"improvements,":[348],"reduced":[349],"polyreactivity,":[350],"improved":[351],"half-life,":[352],"cross-reactivity":[354],"development.":[359]},"counts_by_year":[],"updated_date":"2026-11-09T13:22:03.289127","created_date":"2026-11-04T00:00:00"}